Is OSE.PA undervalued or overvalued?
As of 2025-03-19, the Intrinsic Value of Ose Immunotherapeutics SA (OSE.PA) is
10.49 EUR. This OSE.PA valuation is based on the model Peter Lynch Fair Value.
With the current market price of 6.58 EUR, the upside of Ose Immunotherapeutics SA is
59.43%. This means that OSE.PA is undervalued by 59.43%.
10.49 EUR
Intrinsic Value
OSE.PA Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(102,611.26) - (14,714.88) |
(25,544.62) |
-388316.1% |
| DCF (Growth 10y) |
(11,657,436.43) - (87,046,828.01) |
(20,938,058.34) |
-318207673.6% |
| DCF (EBITDA 5y) |
(5,591.69) - (7,163.72) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(4,436,354.49) - (6,084,954.14) |
(1,234.50) |
-123450.0% |
| Fair Value |
10.49 - 10.49 |
10.49 |
59.43% |
| P/E |
15.95 - 37.56 |
30.06 |
356.8% |
| EV/EBITDA |
19.68 - 25.73 |
24.14 |
266.8% |
| EPV |
(14.27) - (17.79) |
(16.03) |
-343.6% |
| DDM - Stable |
30.61 - 242.00 |
136.31 |
1971.5% |
| DDM - Multi |
(10,299.91) - (62,972.36) |
(17,678.03) |
-268763.1% |
OSE.PA Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
144.37 |
| Beta |
0.83 |
| Outstanding shares (mil) |
21.94 |
| Enterprise Value (mil) |
162.39 |
| Market risk premium |
5.82% |
| Cost of Equity |
6.79% |
| Cost of Debt |
5.00% |
| WACC |
6.29% |